Disclosed herein are novel inhibitors of CD73. More specifically, the novel CD73 inhibitors are derived from benzothiadiazine. Further, the present disclosure is related to the use of said benzothiadiazine derivatives in the treatment of diseases and/or disorders mediated by adenosine, such as AIDS, an autoimmune disease, atherosclerosis, a cancer, an infectious disease, ischemia-reperfusion injury and pre-cancerous syndrome. Also encompassed in the present disclosure are pharmaceutical compositions comprising said benzothiadiazine derivatives.
本文披露了CD73的新型
抑制剂。更具体地说,这些新型CD73
抑制剂是从苯并噻二嗪中派生出来的。此外,本公开涉及使用该苯并噻二嗪衍
生物治疗由
腺苷介导的疾病和/或紊乱,如艾滋病、自身免疫性疾病、动脉粥样硬化、癌症、传染病、缺血再灌注损伤和癌前综合征。本公开还包括包含该苯并噻二嗪衍
生物的制药组合物。